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Abstract
It is a clinical challenge to obtain a sufficient orthopaedic
implant fixation in weak osteoporotic bone. When the
primary implant fixation is poor, micromotions occur at
the bone-implant interface, activating osteoclasts, which
leads to implant loosening. Bisphosphonate can be used to
prevent the osteoclastic response, but when administered
systemically its bioavailability is low and the time it takes
for the drug to reach the periprosthetic bone may be a
limiting factor. Recent data has shown that delivering
bisphosphonate locally from the implant surface could be
an interesting solution. Local bisphosphonate delivery
increased periprosthetic bone density, which leads to a
stronger implant fixation, as demonstrated in rats by the
increased implant pullout force. The aim of the present study
was to verify the positive effect on periprosthetic bone
remodelling of local bisphosphonate delivery in an
osteoporotic sheep model. Four implants coated with
zoledronate and two control implants were inserted in the
femoral condyle of ovariectomized sheep for 4 weeks. The
bone at the implant surface was 50% higher in the
zoledronate-group compared to control group. This effect
was significant up to a distance of 400µm from the implant
surface. The presented results are similar to what was
observed in the osteoporotic rat model, which suggest that
the concept of releasing zoledronate locally from the
implant to increase the implant fixation is not species
specific. The results of this trial study support the claim
that local zoledronate could increase the fixation of an
implant in weak bone.
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Introduction
A current clinical challenge in the field of orthopaedics is
to obtain a stable implant fixation in weak osteoporotic
bone. The fixation of orthopaedic implants in bone relies
strongly upon the initial stability of the implant. When
the initial stability is not achieved, micromotions occur at
the bone implant interface (Mandell et al., 2004;
Ramaniraka et al., 2000). The micromotions then activate
an osteoclastic response (Stadelmann et al., 2008), which
results in periprosthetic osteolysis and later implant
migration and wear (Karrholm et al., 1994). Both
particulate formation from implant wear and implant
migration have been shown to be associated with increased
implant failure rate (Clarke et al., 1992; Horikoshi et al.,
1994). In the case of osteoporotic patients, this early phase
is particularly delicate as the bone is already weak at the
time of surgery. In this case, the resorption of a small
amount of bone near the implant may induce a dramatic
decrease in early fixation, accelerating the failure process.
Bisphosphonate can be used to reduce periprosthetic
osteolysis allowing orthopaedic implants to achieve a
stronger primary fixation (Hilding et al., 2000).
Bisphosphonate molecules inhibit osteoclastic activity,
and therefore are widely used to treat patients with
osteoporosis (Bone et al., 2004; Fleisch, 2002). However,
when administered orally, the bioavailability of
bisphosphonate is generally very low, and its local delivery
can be further delayed in regions of the skeleton with low
blood perfusion, for example the femoral neck. Recent
clinical studies have shown that systemic bisphosphonate
treatment following prosthesis implantation reduced
periprosthetic bone loss only after 3 months (Nehme et
al., 2003; Venesmaa et al., 2001b), while significant bone
loss arises during this initial period of 3 months (Venesmaa
et al., 2001a). A solution to accelerate the local availability
of bisphosphonate at the implant location is to deliver the
drug locally. This insures the immediate presence of drug
molecules at the implant location regardless of the local
blood perfusion.
Implants with local delivery of bisphosphonate have
been studied previously in small animal models and the
results are generally encouraging: In rats, hydroxyapatite
coated implants releasing zoledronate increased
periprosthetic bone density and the pullout force (Peter
et al., 2005); fibrin coated cortical screws releasing
ibandronate and pamidronate increased the pullout force
(Wermelin et al., 2007). Moreover, in dog ulna, Tanzer et
al. showed that local elution of zoledronate can cause
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substantial bone augmentation around and within porous
tantalum implants (Tanzer et al., 2005). Concerning the
osteoporotic bone case, hydroxapatite coated implants
releasing zoledronate increased pullout force and
periprosthetic bone density, compared to control implants
in osteoporotic rats (Peter et al., 2006).
Many differences, such as mineral density, healing
capacity or the response to mechanical stimuli, exist in
the bone metabolism of small animals when compared to
that of humans (Egermann et al., 2005; Holy et al., 2000).
Therefore it is questionable to extrapolate the in vivo results
of small animals into the specific clinical situation of
osteoporotic patients without pre-clinical tests in a large
animal (Buma et al., 2004). To our knowledge, no data
exists concerning local delivery of bisphophonate to
increase fixation strength of an implant in a large
osteoporotic animal model.
Therefore, the aim of the present study was to verify
the efficacy of local bisphosphonate delivery to increase
the periprosthetic bone density in an osteoporotic sheep
model (Turner, 2002).
Materials and Methods
Implants
Six Titanium alloy (TA6V) cylinders (diameter 3 mm;
length 5 mm) were plasma-coated with hydroxyapatite
(thickness: 20 µm; crystallinity index 62%). Two samples
were used as controls, while the remaining 4 samples were
soaked for 48h in 5ml ultrapure water solutions of 2.25 
10-5 mol L-1 of Zoledronate (1-hydroxy-2-[(1H-imidazole-
1-yl)ethylidene] 1-bisphosphonic acid disodium salt)
supplied by Novartis Pharmaceuticals AG, Basel,
Switzerland. The amount of zoledronate loaded onto the
implants was calculated to be 2.1 µg for each implant (Josse
et al., 2004).
Animals and surgical procedures
Animal handling and surgical procedures were conducted
according to the European Community Guidelines for the
care and use of laboratory animals (DE 86/609/CEE) and
approved by the local ethical committee at the Nantes
Veterinary School. Three adult female vendeen sheep with
an average body weight of 55 kg were used in this study.
Six months prior to the study, animals had been neutered
by ovariectomy to induce osteoporosis. Subsequent bone
changes were investigated on iliac crest bone biopsies. A
control biopsy was harvested on the day of ovariectomy
and was compared with a bone sample from the
contralateral iliac crest harvested 6 months later on the
day of implantation. Changes in the microarchitecture of
iliac crest biopsies were investigated through 3D
microtomography analysis.
The tested cylinders were implanted bilaterally for 4
weeks at the distal femoral end of the 3 mature female
sheep. The first animal had two control implants. The
second and third animals had two zoledronate coated
implants. After 2 weeks of acclimatization, general
anaesthesia was induced using an intravenous injection of
4 mg/kg of propofol (Rapinovet®, Schering-Plough,
Levallois-Perret, France) and 0.1 mg/kg of diazepam
(Valium®, Roche, Neuilly-sur-Seine, France). Anaesthesia
was maintained for surgery with a gas mixture of isoflurane
(1.5 %), and oxygen (98.5 %). A single dose of morphine
(0.5 mg/kg) was injected subcutaneously at the beginning
of the surgery as an analgesic. After shaving and
disinfection (Vetedine®, Vetoquinol, Lure, France) of the
knee, a stifle arthrotomy was performed to expose the distal
lateral condyle of the femur.
A cylindrical osseous defect (3 mm in diameter and 6
mm length) was created on the distal femoral epiphysis
using a motor-driven drill (Aesculap, Tuttlingen,
Germany). After saline irrigation, the osseous cavity was
carefully dried and filled with the coated cylinder. The
joint capsule was closed with non-absorbable sutures
(Prolene® 2-0, Ethicon, Issy Les Moulineux, France). The
subcutaneous tissues and skin were closed in different
layers using absorbable sutures (Polysorb® 2-0,
TycoHealthcare, Elancourt, France). Finally, the surgical
wound was covered with an adhesive bandage. Both hind
limbs were operated, giving 2 tested implants per animal.
At the end of surgery, animals received an injection of
meloxicam to complete analgesia (Métacam Bovin®,
Boehringer Ingelheim, Germany) but did not receive any
postoperative antibiotics. The procedure was repeated on
the contra lateral side.
After 4 weeks, general anaesthesia was induced by a
mixed injection of ketamine (Imalgène®1000, Merial,
Lyon, France) and xylazine (Rompun®, Bayer, Puteaux,
France) and the animals were euthanatized by intravenous
injection of  20 ml of pentobarbital (Doléthal®,
Vétoquinol) through a catheter placed into the jugular vein.
The femoral extremities were then dissected from the
surrounding soft tissues and immediately placed in a 10
% neutral formol solution.
Preparation for imaging
The femoral distal ends were then immediately dissected,
fixed in glutaraldehyde solution, and stored in a 4%
paraformaldehyde, 0.1% glutaraldehyde in 0.08 M
cacodylate buffer. Using a handsaw, the condyle was sawed
off 1 cm above the implant. The sample was dehydrated
in a series of alcohol solutions. The first impregnation step
was to soak the sample in a mixture of 50% alcohol 1008
and 50% methyl methacrylate MMA (Fluka Chemika,
Sigma Aldrich Chemie Gmbh, Steinheim, Germany)
during 24 hours. The second impregnation step was to soak
the sample in pure MMA during 24 hours. The first
inclusion step was to soak the dehydrated sample during 2
hours under vacuum in a solution containing 90% MMA,
10% dibutylphtalate (Fluka Chemika) and 1% benzoyl
peroxide (Fluka Chemika). The sample was then removed
from the solution and soaked in the same solution but
enhanced by a polymerization activator (N,N-dimethylp-
toluidine) (Fluka Chemika). The polymerization took place
at -20°C and was complete after 48 hours. Two to four
slices of 300µm thick were cut from each sample, using a
Microtome 1600 (Leica, Nussloch, Germany) diamond
saw. The cutting plane was perpendicular to the implant.
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Scanning Electron Microscopy
Slices were carbon-coated and observed using a JEOL JSM
6300 scanning electron microscope (SEM) (JEOL, Tokyo,
Japan) using the backscattered electron detector, allowing
mineralized bone to be distinguished from soft tissue.
Then, SEM images were used to measure the bone
density as a function of the distance from the coating. The
implant surface and trabecular bone regions were defined
manually on each image. The implant centre and radius
were then calculated by least square fitting of a circle onto
the implant surface. A threshold was applied to the image
in order to distinguish bone from other tissues: pixels with
a gray level between 0 and 62 were considered as calcified
bone, while those with a gray level from 63 to 255 were
considered as other tissues. We defined successive regions
of interests inside the trabecular bone in the form of series
of ten 20µm thick arcs co-centred with the implant. In each
arc, the number of bone pixels was counted and the bone
surface fraction (B.Ar/T.Ar) was defined as bone pixels
divided by total pixels in the arc, using custom algorithms
developed with Image Processing for Mathematica (Fig.
1).
Statistics
The number of slices per group was accounted for as
repetition of the density measurement of the same group.
Student t-test was used to determine the statistical
significance of the results. Wilcoxon test was used to
identify the significant changes of microstructural
properties in the iliac crest biopsies.
Results
A total of 19 slices (6 control, 13 zoledronate-loaded) were
processed (Table 1).
Osteoporosis induction
Significant microstructural evolutions were measured on
the iliac crest biopsies (Fig. 2). The bone volume fraction
(BV/TV) decreased by 30% at six months post-
ovariectomy. While trabecular thickness (Tb.Th),
trabecular number (Tb.N) and trabecular separation
(Tb.Sp) decreased by 11%, 19%, and increased by 14%
respectively; the structural model index (SMI) was not
significantly affected (Table 2).
Implant integration
The implant integration was verified qualitatively during
backscattered electron microscopy imaging. We observed
homogenous bone-implant contact as well as new bone
formation along the coating surface. Lacunae were
observed in the bone speckles growing from the coating.
Different levels of mineralization were observed in the
newly formed bone. The coating was partially resorbed,
and new bone was observed in the resorption zones (fig.
3).
Table 1: Number of animals, implants and slices per
group
Table 2: Microstructure data of iliac crest biopsies obtained before ovariectomy (Control) and the day of implantation
(OVX), data as Mean±SD. The evolution column shows significant changes (p<0.05). The relative evolution of
bone architecture parameters emphasises osteoporosis induction.
Figure 1: Schematic of the method used to determine
the bone surface fraction profile. At a distance x from
the coating surface, a region of interest (ROI) was
defined as an annulus of 20µm thickness co-centred
with the implant of radius R+x, where R is the implant
radius. Then the number of bone pixels inside the ROI
(blue pixels) was divided by the total number of pixels
in the ROI (blue+yellow pixels). The distance x was
incremented from 0 to 1mm in steps of 20µm.
Control OVX Evolution (%)
BV/TV (%) 19.0 ± 3.3 13.3 ± 1.3 -30
Tb.Th (!m) 144.1 ± 15.8 128.0 ± 11.1 -11
Tb.N (10-3/!m) 1.32 ± 0.14 1.07 ± 0.15 -19
Tb.Sp (!m) 683 ± 56 783 ± 66 +14
SMI 0.86 ± 0.23 0.90 ± 0.18
Control Zoledronate
Sheep 1 2
Implants 2 4
Slices 6 13
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Bone surface fraction
The bone surface fraction (B.Ar/T.Ar) in a 20µm-thick
layer around the implant was 50% higher in the zoledronate
group compared to the control group (B.Ar/
T.Ar=0.45±0.08 for the zoledronate group, 0.30±0.07 for
the control group, p<0.05). B.Ar/T.Ar of the zoledronate
group decreased from 0.45±0.08 at the coating surface to
0.30±0.05 at 800µm from the coating, while the profile of
the control group was almost constant (figure 4a). The
difference between B.Ar/T.Ar of the zoledronate group
and the control group was significant up to 400µm from
the coating (figure 4b). The total bone area (B.Ar) in
400µm-thick layer around the implant was 10% greater in
zoledronate group compared to control group (p<0.05)
(fig.4c).
Discussion
Implants locally delivering bisphosphonate have been
shown to increase periprosthetic bone density and pullout
forces in previous studies using rat models (Kajiwara et
al., 2005; Wermelin et al., 2007). However, the bone
metabolism of healing and remodelling in rats is different
in humans (Buma et al., 2004; Egermann et al., 2005).
Therefore, a large animal study was necessary to validate
these results for later applications to human patients with
osteoporotic bone. In this study, our aim was to use the
osteoporotic sheep model to verify the efficacy of locally
delivering zoledronate from an orthopaedic implant to
increase the periprosthetic bone density.
Our results showed that B.Ar/T.Ar in a 20µm layer
was increased by 50% in the locally delivered-zoledronate
group compared to the control group in osteoporotic sheep.
The effect of local delivery of zoledronate on B.Ar/T.Ar
was significant up to 400µm distance from the implant.
The mean B.Ar/T.Ar in the 400µm region around the
implant was increased by 10% in the zoledronate-group
compared to the control group.
Figure 2: Three-dimensional microtomographic
description of iliac crest biopsies microarchitecture (a)
before ovariectomy and (b) 6 months after
ovariectomy. The difference illustrates the induction
of osteoporosis.
Figure 3: SEM pictures of three slices of implants; (a)
Local bone structure of a condyle implanted with an
HA-coated implant (i) containing 2.1µg zoledronate;
(b) Local bone structure of a condyle implanted with a
control implant (i); (c) Details of the osseointegration
of an zoledronate-implant (i) shows bone growth into
resorbed spaces of the coating. Osseointergation in
control implants was qualitatively similar.
The implant and dose of zoledronate used in the sheep
condyles are identical to those implanted for three weeks
in previous rat and OVX rat models (Peter et al., 2005,
2006). The experimental timeline for the sheep was chosen
to be four weeks as to compensate for the possibility of a
slower remodelling rate in larger animals. When the results
of these different models were compared (Table 2), we
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observed: In non-osteoporotic rats, zoledronate coated
implants induced an increase of 43% of B.Ar/T.Ar at the
implant surface, while in osteoporotic rats the increase was
20% at 3 weeks post-surgery. In the present osteoporotic
sheep model, at 4 weeks post-surgery, we observed an
increase of 50%, which is significantly greater than the
effect in rats. Moreover, the distance from the implant over
which the effect of zoledronate is significant is five times
greater in osteoporotic sheep than in osteoporotic rats.
The observed difference cannot be explained simply
with this data. It can be related to prolongation of one week
in the post-surgery delay, to an enhanced reaction of sheep
bone cells to zoledronate, or to the initial difference in
bone density. Despite the questions that remain
unanswered, these results show that a small dose of
zoledronate delivered locally in osteoporotic sheep bone
efficiently increases periprosthetic bone density in a way
similar to what was previously observed in rats.
This result is concordant with the very recent study of
Goodship et al., in which intravenous administration of
zoledronate pre- peri- and postsurgery reduced
periprosthetic cortical osteopenia in a sheep model of hip
replacement (Goodship et al., 2008). Therefore,
zoledronate treatments seem to have a beneficial action
on periprosthetic bone, cortical or trabecular.
The goal of local bisphosphonate release is to increase
the implant fixation strength, but a complete pullout study
would have required supplementary animals. Pullout force
is mainly influenced by bone density in a thin layer of
bone, extending 20µm radially from the implant (Peter et
al., 2005). In osteoporotic rats, an increase of 20% of bone
volume fraction in the 20µm layer induced nearly a 100%
increase in pullout force (175±70N with 2.1µg compared
to 90±30N for controls). However, the exact effect on
pullout force in the sheep model cannot be calculated from
rat models, as the scale of bone trabeculae and the bone
density are very different in these species. But, with more
than 2-fold increase in bone volume fraction in the 20µm
layer, it is likely that an increase in pullout force would be
observed as well in the present study.
Zoledronate, like other bisphosphonates, has been
shown to limit bone loss in patients with osteoporosis
(Glatt, 2001), while also inducing a beneficial impact on
microarchitectural properties of trabecular bone (Poole et
al., 2007; Recker et al., 2008). In the present study we did
not assess other microarchitectural properties of
periprosthetic bone than B.Ar/T.Ar. However, some of
these properties, such as the bone volume fraction are
mathematically linked to B.Ar/T.Ar (Parfitt et al., 1987;
Revell, 1983).
Clinical relevance of the study
The clinical aim of coating orthopaedic implants with
zoledronate is to improve the fixation of orthopaedic
implants in patients with weak bone. Benefits of
zoledronate local delivery were previously observed in
osteoporotic rats. The present study further extended these
results to a large animal model. The measured increase of
Table 3: Comparison of the effect of 2.1µg zoledronate / implant versus control on periprosthetic B.Ar/T.Ar in a
20µm layer, and distance of the effect from the implant. Rats and osteoporotic rats data adapted from (Peter et al.,
2005) and (Peter et al., 2006), respectively.
Figure 4: (a) Bone surface fraction (Mean±SEM) as a function of the distance from the implant coating. (b) Student
t-test’s p-value of B.Ar/T.Ar comparison between zoledronate-group and control-group as a function of the distance
from the coating: the effect of local zoledronate is significant up to 400µm from the coating. (c) Total periprosthetic
bone surface in a 400µm thick layer around the implant for zoledronate group and control group (Mean±SD,
*: p<0.05, compared to control, SD were calculated from the number of slices per group which were accounted for
as repetition of the density measurement of the same group).
B.Ar/T.Ar B.Ar/T.Ar Relative Distance of
Control Zoledronate Increase the effect
Rats 0.48±0.04 0.69±0.03 43% 250µm
OVX rats 0.46±0.03 0.55±0.03 20% 70µm
OVX sheep 0.30±0.07 0.45±0.08 50% 400µm
15
V.A Stadelmann et al.                                                                                               Implants delivering bisphosphonate locally
periprosthetic bone density supported that local
zoledronate delivery significantly improves the implant
fixation in osteoporotic sheep.
To further validate the use of implants with local
zoledronate delivery, the next set of experiments should
be performed with full load bearing implants to quantify
the combined effects of mechanical stimulus and
zoledronate release to the response of periprosthetic bone.
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Discussion with Reviewers
J. Green: In the absence of extensive clinical data, the
relative practical benefits of local versus systemic
bisphosphonate delivery are still debatable. Whilst local
delivery from a coated implant may reduce the risk of side
effects, a patient requiring an implant is likely to have
osteoporosis at other sites and would thus benefit from
systemic drug exposure. Moreover, after a surgical
intervention to implant a prosthesis, the surrounding bone
is highly active and shows enhanced bisphosphonate
uptake, calling into question the need for local delivery
from coated implants.
Authors: Some patients requiring orthopaedic implants
are likely to have osteoporosis. Regarding these patients:
in cases of undiagnosed and untreated disease, a
zoledronate-coated implant would certainly offer benefits
compared to uncoated implants, as indicated by the present
pilot study. In cases of patients already treated with
bisphosphonate, there is no experimental evidence that
zoledronate-coating would provide a better fixation than
a systemic administration. However, while zoledronate-
coating provides an immediate release of a very small
amount of drug at the desired location (which in this case
is independent of the rate of activity of the surrounding
bone), systemic treatment provides a continuous drug
uptake on a long-term basis. Thus, the optimal implant
fixation in patients with osteoporosis may be obtained by
a combined approach of local and systemic treatment,
rather than one or the other, taking advantages of both
approaches. However, this hypothesis has yet to be
demonstrated experimentally.
D. Little: This small paper suggests the possibility that
local bisphosphonates can improve osseointegration of
implants. Do authors have any estimate on the duration of
such a positive effect?
Authors: Our objective was to obtain an increase of
fixation at short-term. Indeed, clinical data suggests that a
good short-term implant fixation is generally followed by
a strong long-term fixation, when compared to implant
with early loss of fixation. Based on these results, we
believe that the benefit observed after 4 weeks should last
for much longer. But, the duration of the beneficial effect
depends on many factors such as the mechanical
environment and the rate of elimination of the drug, thus
the exact duration remains to be determined
experimentally.
R.G. Richards: The reduced bone volume / trabecular
volume is taken as an osteoporotic model of osteoporosis.
Is this really a model of osteoporosis or osteopaenia? Do
the authors think that any sheep model is actually a realistic
model of osteoporosis or more of osteopaenia?
Authors: To be exact the presented data is a model of
severe osteopaenia. There are actually no animal models
that realistically reflect the human condition of
osteoporosis. However, to our knowledge the OVX sheep
model is the best model available to study orthopaedic
applications in osteoporotic bone (see Turner, 2002).
J. Green: As bone loss in the ovine osteoporosis model
can be influenced by breed, season, diet etc, the omission
of any data to confirm the extent of the osteopaenia/
osteoporosis in these 3 animals is a concern. This could
have been partially addressed by using each animal as its
own control with a zoledronate coated implant in one femur
and an uncoated control implant on the contra-lateral side
– I doubt whether there would have been any systemic
drug exposure from the coated implant.
Authors: Strictly speaking the condition of these animals
is osteopaenia (based on BV/TV standard deviations) but
the severe bone loss of 30% detected in iliac crests biopsies
suggests that this model is somewhat comparable to
osteoporosis condition in some human bones. Indeed, when
planning the study, our concern was that the drug could
influence the contra-lateral side bone density, which is why
we did not use each animal as its own control. A posteriori,
the extent of the effect of the drug is very limited (400µm)
and thus there would certainly be no systemic effect. This
supports the own-control design in the future.
R.G. Richards: Long term bisphosphonates have been
seen to increase cortical bone thickness in elderly
osteoporotic patients, yet recently it has been observed
that this new cortical bone is very brittle and if fractured,
very difficult to repair. I assume this is because the natural
remodelling is knocked out by the bisphosphonates and
the osteoclasts no longer function. What effect would local
bisphosphonates have on the quality of the osseointegrated
bone formed?
Authors:  In the case of patients not exposed systemically
to bisphosphonate in parallel to the presented technique,
we do not think the quality of the bone is an issue on a
long-term perspective: the coated dose is available in the
bone only once and is slowly retrieved from the coating
and from the surrounding bone with normal metabolic
processes. Therefore the remodelling of the periprosthetic
bone should be reactivated after some time, and the
damaged bone renewed.
